Search
forLearn
5 / 801 resultslearn AHAs
learn APISCALP™
learn ABN Complex
learn 3 aminopropane Sulfernic acid
Research
5 / 78 results
research A role for the Tgf-β/Bmp co-receptor Endoglin in the molecular oscillator that regulates the hair follicle cycle
Endoglin is crucial for proper hair growth cycles and stem cell activation in mice.
research Activin A-induced signalling controls hair follicle neogenesis
Activin A is important for creating new hair follicles.
research Cationic Ionic Liquid-Liposome Nanoplatform for Transdermal asiRNA Delivery: A Unified Therapy for Androgen-Dependent Dermatoses
research Therapeutic small extracellular vesicles from key human stem and immune cellular sources: A review
Small extracellular vesicles from stem and immune cells show promise for treating various diseases but face challenges in clinical use.
research ISID1343 - Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia
The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.
Community Join
5 / 1000+ resultscommunity Since there is so much hype for cosmeRNA and HMI-115...
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
community ASATONA AG and "Asatex"
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.